用于合成代谢类固醇诱导性心肌病心室恢复的左心室辅助装置
Left ventricular assist device for ventricular recovery of anabolic steroid-induced cardiomyopathy.
作者信息
Luc Jessica G Y, Buchholz Holger, Kim Daniel H, MacArthur Roderick G G
机构信息
Division of Cardiac Surgery, Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada.
出版信息
J Surg Case Rep. 2018 Aug 15;2018(8):rjy221. doi: 10.1093/jscr/rjy221. eCollection 2018 Aug.
Herein we report a case of a 26-year-old gentleman with severe cardiomyopathy likely secondary to anabolic-androgenic steroid (AAS) abuse who received a HeartMate II (Abbott Laboratories, Abbott Park, IL) left ventricular assist device (LVAD) for rapidly deteriorating heart failure with hemodynamic compromise. Following 18 months on LVAD support, excellent recovery of ventricular function was achieved to allow for LVAD discontinuation. Given that active substance abuse is a contraindication to heart transplantation, few options remain for patients with AAS induced heart failure. Our case demonstrates that LVAD therapy can be an important intervention for bridging to candidacy, recovery or destination therapy.
在此，我们报告一例26岁男性患者，患有严重心肌病，可能继发于合成代谢雄激素类固醇（AAS）滥用，因心力衰竭迅速恶化并伴有血流动力学障碍，接受了HeartMate II（雅培实验室，伊利诺伊州雅培公园）左心室辅助装置（LVAD）治疗。在接受LVAD支持18个月后，心室功能实现了出色恢复，得以停用LVAD。鉴于药物滥用是心脏移植的禁忌证，AAS诱导的心力衰竭患者的选择很少。我们的病例表明，LVAD治疗可以是一种重要的干预措施，用于过渡到候选资格、恢复或终末治疗。
Zotero 插件